PRX, ALKS, Initiated At Buy

Joe Young

September 30, 2010 10:23am Comments

UBS has initiated coverage for the following companies:

Par Pharmaceutical Companies (NYSE: PRX) Buy, $35 price target

Alkermes Inc. (NASDAQ: ALKS) Buy, $18 price target

Posted-In: alkermes par pharmaceutical UBS Initiation Analyst Ratings

Need analyst data?
Click here to see licensing options.

Stock	Firm	Action	PT
SEDG	B of A Securities	Maintains	411.0
PTLO	Piper Sandler	Maintains	28.0
AOUT	Lake Street	Maintains	26.0
RAPT	Piper Sandler	Maintains	52.0
OCX	Lake Street	Maintains	6.0

1	ETN: Here's How Much $1000 Invested In Eaton Corp 5 Years Ago Would Be Worth Today
2	XLK, QQQ: This Nasdaq 100 Signal Last Flashed In 1999—What Came Next Was Insane
3	GM: General Motors Faces Tariffs Heat, Margins Shrink
4	MEDP, COF: Lockheed, General Motors Tumble, Gold Hits 1-Month Highs:...
5	CNQ: Here's How Much $1000 Invested In Canadian Natural...
6	RIVN, TSLA: Trump's New ZEV Credit Regulations Aren&...
7	How I Built a Portfolio That Outperforms in E...

1	$SHIB, $BTC: Bitcoin, Ethereum, XRP, Dogecoin Slide Despite Equities Rally
2	IYW, QQQ: Betting On A Post-Earnings Pop? These ETFs Have Alphabet Writ...
3	DHI: D.R. Horton Leverages Small‑Market Growth To Fuel Moment...
4	SRPT: Elevidys Halt Sparks Analyst Downgrades—Sarepta Race...
5	MRNA: What's Going On With Moderna Stock Wednesday?
6	AMZN, MSFT: Amazon's AI-Powered AWS, Efficiency...
7	RBLX: What's Going On With Roblox Sha...

Market Overview